This review summarizes the clinical and molecular characteristics of genetic entities with aberrant HOXA/B/MEIS1, agents targeting the menin-KMT2A interaction and other molecular vulnerabilities in assembly of protein complexes or general transcription machinery as well as implications of these evolving therapies in childhood AML. The gene discussed is KMT2A; the disease is acute myeloid leukemia.